ATHE Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 38.80%

Insider Buying (Last 12 Months): $23,810.00

Insider Selling (Last 12 Months): $0.00

Alterity Therapeutics Insider Trading History Chart

Alterity Therapeutics Share Price & Price History

^$4.51

▼ -0.03 (-0.66%)

As of 09/8/2026 04:00 PM ET

Days: 30 | 90 | 365

Alterity Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/31/2026	Peter Ashley Marks	Director	Buy	47,620	$0.50	$23,810.00	191,340

SEC Filings (Institutional Ownership Changes) for Alterity Therapeutics (NASDAQ:ATHE)

2.14% of Alterity Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Alterity Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/20/2026	Greenleaf Trust	62,000	$0.33M	0.0%	+93.8%	0.699%
11/17/2025	Citadel Advisors LLC	22,144	$83K	0.0%	N/A	0.250%
10/23/2025	HB Wealth Management LLC	58,460	$0.22M	0.0%	N/A	0.659%
10/22/2025	Greenleaf Trust	32,000	$0.12M	0.0%	+88.2%	0.361%
10/21/2025	Twin Lakes Capital Management LLC	139,258	$0.52M	0.2%	+2,250.3%	1.570%
7/17/2025	Greenleaf Trust	17,000	$70K	0.0%	N/A	0.192%
5/7/2025	HB Wealth Management LLC	37,483	$0.13M	0.0%	+17.6%	0.423%
2/17/2025	Point72 Asset Management L.P.	32,627	$0.11M	0.0%	N/A	0.373%
2/17/2025	BNP Paribas Financial Markets	8,790	$29K	0.0%	N/A	0.101%
1/15/2025	HB Wealth Management LLC	31,883	$0.11M	0.0%	+34.1%	0.436%

Data available starting January 2016

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Today's Range

Now: $4.51

$4.45

$4.55

50 Day Range

MA: $4.78

$4.37

$5.89

52 Week Range

Now: $4.51

$2.66

$5.89

Volume

16,172 shs

Average Volume

17,598 shs

Market Capitalization

$81.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27

Who are the company insiders with the largest holdings of Alterity Therapeutics?: Alterity Therapeutics' top insider shareholders include:
Peter Ashley Marks (Director)
Learn More about top insider investors at Alterity Therapeutics.
Who are the major institutional investors of Alterity Therapeutics?: Alterity Therapeutics' top institutional investors include:
Greenleaf Trust — 0.70%
Learn More about top institutional investors of Alterity Therapeutics stock.
Which institutional investors are buying Alterity Therapeutics stock?: Within the previous quarter, ATHE stock was acquired by institutional investors including:
Greenleaf Trust